Head-To-Head Comparison: CG Oncology (CGON) versus Its Rivals

CG Oncology (NASDAQ:CGON) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare CG Oncology to related businesses based on the strength of its analyst recommendations, earnings, valuation, profitability, institutional ownership, risk and dividends.

Valuation & Earnings

This table compares CG Oncology and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CG Oncology	$1.14 million	-$48.61 million	-19.54
CG Oncology Competitors	$575.26 million	-$70.96 million	-2.05

CG Oncology’s competitors have higher revenue, but lower earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for CG Oncology and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	0	1	9	1	3.00
CG Oncology Competitors	1973	5466	14073	305	2.58

CG Oncology currently has a consensus target price of $59.56, indicating a potential upside of 114.69%. As a group, “Biological products, except diagnostic” companies have a potential upside of 118.01%. Given CG Oncology’s competitors higher probable upside, analysts plainly believe CG Oncology has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

CG Oncology has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, CG Oncology’s competitors have a beta of -4.48, suggesting that their average stock price is 548% less volatile than the S&P 500.

Profitability

This table compares CG Oncology and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CG Oncology	-10,642.98%	-18.97%	-15.36%
CG Oncology Competitors	-2,185.76%	-161.46%	-40.62%

Summary

CG Oncology beats its competitors on 7 of the 13 factors compared.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.